Objective: Assessment of the effectiveness and safety of high daily 125 mg (5000 IU) or 250 mg (10 000IU) doses of vitamin D 2 during 3 months, in rapidly obtaining adequate 25 hydroxyvitamin D (25OHD) levels. Design: Longitudinal study. Subjects: Postmenopausal osteopenic/osteoporotic women (n ¼ 38) were studied during winter and spring. Median age (25-75th percentile) was 61.5 (57.00-66.25) years, and mean bone mineral density (BMD) was 0.902 (0.800-1.042)g/cm 2 . Subjects were randomly divided into three groups: control group (n ¼ 13): no vitamin D 2 , 125 mg/day (n ¼ 13) and 250 mg/day (n ¼ 12) of vitamin D 2 groups, all receiving 500 mg calcium/day. Serum calcium, phosphate, bone alkaline phosphatase (BAP), C-telopeptide (CTX), 25OHD, mid-molecule parathyroid hormone (mmPTH), daily urinary calcium and creatinine excretion were determined at baseline and monthly. Results: For all subjects (n ¼ 38), the median baseline 25 hydroxyvitamin D (25OHD) level was 36.25 (27.5-48.12) nmol/l. After 3 months, 8% of the patients in the control group, 50% in the 125 mg/day group and 75% in the 250 mg/day group had 25OHD values above 85 nmol/l (34 ng/ml). Considering both vitamin D 2 groups together, mmPTH and BAP levels diminished significantly after 3 months (Po0.02), unlike those of CTX. Serum calcium remained within normal range during the follow-up. Conclusions: The oral dose of vitamin D 2 required to rapidly achieve adequate levels of 25OHD is seemingly much higher than the usual recommended vitamin D 3 dose (20 mg/day). During 3 months, 250 mg/day of vitamin D 2 most effectively raised 25OHD levels to 85 nmol/l in 75% of the postmenopausal osteopenic/osteoporotic women treated.
Introduction
Vitamin D insufficiency -determined by 25 hydroxyvitamin D (25OHD) serum levels-is common in elderly populations (particularly in institutionalized subjects) (Mc Kenna, 1992) and leads to secondary hyperparathyroidism, high bone turnover, bone loss and osteoporotic fractures (Brazier et al., 1995; Chapuy et al., 1996; Dawson-Hughes et al., 1997; Boff et al., 1999; Oliveri et al., 2004) . The threshold of serum 25OHD that separates vitamin D sufficiency from insufficiency has largely been defined by its biological effect, primarily by the increase in serum parathyroid hormone (PTH) .
Reports in the literature have established serum 25OHD levels below which PTH begins to rise to be between 30 and 50 nmol/l (12-20 ng/ml) (Bouillon et al., 1987; Gloth et al., 1995; Ooms et al., 1995; Mc Kenna and Freaney, 1998) . Other authors have proposed higher levels of 25OHD as limits of insufficiency: 62.5, 77.5 or 110 nmol/l (Chapuy et al., 1992; Dawson-Hughes et al., 1997; Haden et al., 1999) . Prior studies performed on elderly people in our country established a cutoff level of 67.5 nmol/l (Oliveri et al., 2004) . Furthermore, administration of vitamin D supplements to attain mean 25OHD levels between 72.5 and 110 nmol/l decreased the incidence of osteoporotic fractures (Chapuy et al., 1992; Dawson-Hughes et al., 1997; Trivedi et al., 2003) . A group of experts on vitamin D proposed that patients with minimum desirable 25OHD level clusters between 70 and 80 nmol/l to be at lower risk of fracture (Dawson-Hughes et al., 2005) . Heaney et al. (2003b) proposed a different parameter to establish adequate 25OHD levels: optimal intestinal calcium absorption. The authors reported that 25OHD levels in the elderly should be above 85 nmol/l. Even though there is no consensus on this 'adequate' level of 25OHD, we considered 85 nmol/l as the desirable level to be achieved, taking into account the importance of calcium intestinal absorption in skeletal balance. The same group of investigators found that a group of young adult men needed an average daily vitamin D intake (supplement food and tissue store) of approximately 95 mg/day to sustain 'normal' 25OHD levels during winter. Administration of 125 or 250 mg/day of oral vitamin D 3 per day during 20 weeks resulted in 25OHD levels between 150 and 200 nmol/l (from a baseline level of 67.5 nmol/l, but no abnormal levels of serum calcium were observed) (Heaney et al., 2003a) . To our knowledge, there are no previous studies on the dose of oral vitamin D 2 needed to rapidly produce adequate increments in 25OHD levels in postmenopausal women who need to be treated for osteoporosis. This information is of particular importance considering that oral vitamin D 3 treatment regimens are able to induce a significant reduction in bone fractures in men and women over the age of 65years (Chapuy et al., 1992; Trivedi et al., 2003) . In addition, it has been reported that adequate levels of vitamin D enhance response to antiresorptive therapy for osteoporosis (Koster et al., 1996; Yamanaka et al., 2004) .
The aim of our study was to evaluate whether administration of high daily doses (125 and 250 mg) of vitamin D 2 during 3 months allowed to obtain desirable 25OHD levels (above 85 nmol/l) rapidly.
Subjects
Seventy women seen at the outpatient's section of the Hospital de Clínicas, who presented spontaneously for bone mass evaluation, were asked to participate in the study. All subjects were aged between 50 and 70 years, had started menopause at least 1 year prior to the study, and lived in Buenos Aires (latitude 341S).
Screening
Sixty five women agreed to participate, five of whom were excluded on the basis of the following exclusion criteria: (1) treatment with vitamin D or any other medication known to affect mineral metabolism, within 12 months prior to the study; (2) a health condition which rendered administration of vitamin D unadvisable (renal lithiasis, tumors) or affecting vitamin D metabolism (hepatic disease, renal insufficiency).
Densitometry of the lumbar spine or femoral neck and biochemical determinations of mineral metabolism were performed on the remaining 60 women, after obtaining their written informed consent. Densitometry of the lumbar spine (LS) or femoral neck (FN) was performed by DXA (LUNAR DPX-L) and the results were compared with normal reference values to calculate T score (Vega et al., 1993) .
Five patients presented hypercalciuria and 10 failed to meet densitometric inclusion criteria: bone mineral density (BMD), T score of LS or FN below À1. The final study population comprised 45 women who were randomly assigned to one of three three treatment groups. All patients received an oral dose of 500 mg/day of calcium in the form of calcium carbonate (1 tablet/day) and they were randomly assigned to receive one of the following treatments for 3 months: control group: no vitamin D 2 (n ¼ 13); 125 mg/day (5000 IU/day) of vitamin D 2 (n ¼ 13); and 250 mg/day (10 000 IU/day) of vitamin D 2 (n ¼ 12). Vitamin D 2 (the only pharmaceutical preparation of vitamin D alone, available in Argentina) was administered in the form of oral drops. The vials containing vitamin D 2 were supplied by Spedrog-Caillon (Buenos Aires, Argentina). The vitamin D 2 solution was analyzed blindly by a laboratory using liquid chromatography; the concentration was found to be 62.5 mg per drop.
Randomization and design
Patients in the 125 mg/day group received two daily drops and those in the 250 mg/day group received four daily drops. Compliance with calcium and vitamin D 2 regimens was assessed by pill counts and drop counts in each box and vial returned to us at each monthly visit. Seven patients dropped out of the study during follow-up (two from the control group, two from the 125 mg/day group and three from the 250 mg/day group): four women for personal reasons, one underwent emergency colecystectomy, one was diagnosed with primary hyperparathyroidism -previously masked because of vitamin D deficiency, and one failed to comply with the instructions. We report the results obtained from the 38 patients who completed the treatment, and whose baseline characteristics were (median) (25-75th percentile): 61.5 (57.0-66.2) years old, 65.5 (58.0-72.25) kg weight, 1.55 (1.51-1.58) m height, 26.6 (23.3-30.6) kg/m 2 body mass index (BMI) and 0.902 (0.800-1.042) g/cm 2 BMD.
Materials and methods

Biochemical determinations
Fasting blood and 24 h urine samples were collected from all the patients before the onset of the study and monthly throughout the study. All serum and urine samples were frozen and stored until processed. The side effects evaluated for safety were the presence of hypercalcemia (serum calcium 410.5 mg/dl) and hypercalciuria (urinary calcium 4250 mg/ 24 h or calciuria/creatininuria ratio 40.37 mg/mg) (Vieth et al., 2001) . Serum calcium, 24 h urinary calcium and creatinine excretion were determined each month before giving the patient a new vial of vitamin D 2 and a new box of calcium tablets. Serum calcium, phosphate, urinary calcium and creatinine determinations were performed using standard techniques.
Bone alkaline phosphatase (BAP) (reference range: 31-95 IU/l) was determined by agglutination with wheat germ (Farley et al., 1994) . Serum levels of 25OHD were determined by radioimmunoassay (DIASORIN). Inter-and intra-assay coefficients of variation (CV) were 19 and 7.6%, respectively. PTH was measured by radioimmunoassay using an antiserum against the mid-and terminal carboxyl groups of the molecule (mmPTH) (reference range: 20-100 pg/ml) (Arnaud et al., 1971) .
Serum C-terminal crosslinking telopeptide of type I collagen (CTX) (reference range: 14-450 ng/ml) was measured by electrochemical luminescence (Roche Elecsys 1010); intra and interassay CV were 1.6 and 6.1%, respectively. All samples for 25OHD, mmPTH , CTX and BAP determinations were analyzed in the same assay and processed simultaneously at the end of the follow-up period in order to minimize interassay variation.
Statistical analyses
Statistical analysis was performed using SPSS 11.0 for Windows (SPSS, Inc., Chicago, IL, USA). Comparisons between groups, at different time points, were established using a nonparametric unpaired test (Mann-Whitney).
Comparison between baseline and follow-up values in each group was performed using a nonparametric paired test (Wilcoxon). A value of P below 0.05 was considered significant. Table 1 shows the baseline characteristics of the patients arranged according to treatment groups. None of the studied variables showed significant differences among groups.
Results
Compliance
The mean rates of compliance with treatment on the basis of pill and drop counts were (X7s.d.) 89711 and 92710%, respectively. Table 2 shows 25OHD medians values of the three groups throughout the 3 months follow-up. No changes in 25OHD values were observed throughout the study period in the control group. Values increased significantly in the 125 and 250 mg/day groups after 1 month of treatment (Po0.01). The values increased from 42.0 (23.7-45.0) nmol/l at baseline to 77.5 (66.2-56.2) nmol/l, after 3 months treatment in the 125 mg/day group (Po0.001 vs baseline), and from 32.5 (27.5-45.0) nmol/l to 97.7 (79.3-123.1) nmol/l in the 250 mg/ day group (Po0.01). After 2 and 3 months of treatment, average 25OHD levels in the 250 mg/day group were higher than those in the 125 mg/day group, although the difference was not statistically significant (0.14P40.05). Figure 1 shows individual 25OHD serum values at baseline and after 3 months of treatment. Considering a cutoff value of 85 nmol/l, one out of 13 patients in the control group exhibited higher values at baseline and throughout the study; however, none of the remaining patients in this group with lower baseline values reached this level. All baseline values in the 125 mg/day group were below 52.5 nmol/l, yet six out of 12 patients (50%) showed values above 85 nmol/l after 3 months of treatment. Nine out of 12 patients (75%) reached levels of 25OHD above the same limit after 3 months in the 250 mg/day group. If we consider a different cutoff level of 67.5 nmol/l, 77 and 100% of patients in the 125 or 250 mg/day groups, respectively, after 3 months were above this level, whereas the corresponding percentage for controls was only 23%.
Changes in serum 25OHD
Changes in PTH
Serum mmPTH values obtained throughout the study in each of the three groups are shown in 
Safety
Average serum calcium levels remained unchanged in the control and in the 125 mg/day group. The average value in the 250 mg/day group was found to increase significantly after 2 months of treatment (Po0.05). Analysis of results, considering both vitamin D 2 -treated groups as a whole, showed an increase in serum calcium levels from 9.3 [8.9-9.6] mg/dl at baseline to 9.6 [9.3-9.9] mg/dl after 3 months treatment (Po0.05). However, no individual value in any of the three groups was above the upper limit of the normal range (10.5 mg/dl). One patient in the 125 mg/day group exhibited values above 250 mg/24 h at 2 and 3 months (312 and 340 mg/24 h, respectively) compared to a baseline value of 172 mg/24 h. One patient in the 250 mg/day group showed an increase from a baseline value of 229-278 mg/24 h after 3 months treatment. One patient in the control group exhibited hypercalciuria (4250 mg/24 h), with values reaching 358 mg/24 h at 3 months compared to 202 mg/24 h at baseline. Urinary calcium excretion was below 250 mg/24 h in all the remaining cases. There were no differences among groups at any of the studied times points when comparing the number of patients with urinary calcium levels higher than 250 mg/24 h. None of the subjects showed a calciuria/creatininuria ratio 40.37 mg/mg during the follow-up.
Discussion
Vitamin D 3 is an important therapeutic agent used in osteoporosis treatment, since several studies have proven its efficacy in preventing bone fragility-associated fractures (Chapuy et al., 1992; Dawson-Hughes et al., 1997; Trivedi et al., 2003; Bischoff et al., 2005) . Some studies have suggested that one important effect of vitamin D is that it improves muscular function, which in turn would contribute to reducing falls (Pfeifer et al., 2002; Bischoff et al., 2003) . The mechanisms most frequently associated with vitamin D effects are an increase in intestinal calcium absorption, a decrease in PTH secretion, and a diminution in the rate of bone remodeling (Chapuy et al., 1992; DawsonHughes et al., 1997) . However, few studies have attempted to determine the optimal dose of vitamin D required to rapidly achieve the aforementioned changes in patients with osteopenia/osteoporosis without causing hypercalcemia. Heaney et al. (2003b) established that serum 25OHD levels should be above 85 nmol/l in order to obtain optimal intestinal calcium absorption. This level of serum 25OHD is not very different from that found in other studies establishing the optimal level of 25OHD to be between 62.5 and 110 nmol/l, in order to avoid increases in PTH serum levels and to reduce the incidence of osteoporotic fractures (Chapuy et al., 1992; Dawson-Hughes et al., 1997; Haden et al., 1999; Trivedi et al., 2003; Oliveri et al., 2004; Dawson-Hughes et al., 2005) . The studies performed on Caucasian women who received vitamin D 2 or D 3 to treat and/or prevent osteoporosis have shown wide variations as regards the dose employed and the time points used for follow-up determinations. Chapuy et al. (1992) found that administration of 20 mg/day of vitamin D 3 increased 25OHD levels from 40 to 105 nmol/l after 18 months of treatment, but levels of 25OHD at shorter periods are not reported. A 100 mg/day dose of vitamin D 3 have been used by Vieth et al. (2001) in young men and women, increasing 25OHD levels from 40 to 97.5 nmol/l at 3 months; the levels remained unchanged after 5 months treatment. In the same study, the author reported that administration of 25 mg/day of vitamin D 3 increased 25OHD levels from 40 nmol/l at baseline to 67.5 nmol/l at 3 months, finding no changes after 5 months of treatment. In older people, the same authors (Vieth et al., 2004 ) administered doses of 15 and 100 mg/day of vitamin D 3 during more than 6 months and observed a higher improvement of well-being score in the higher vitamin D 3 dose group. Other studies using different oral doses (10-20 mg/day) with baseline 25OHD levels o50 nmol/ml (range: 7.5-47.0) failed to achieve average 25OHD levels above 67.5 nmol/l (Brazier et al., 1995; Lips et al., 1996; Meyer et al., 2002) . Tangpricha et al. (2003) administered 25 mg/day of vitamin D 3 in orange juice to a group of normal young adults, obtaining an important mean increase in 25OHD levels from 37 to 94 nmol/l in 12 weeks. In turn, Malabanan et al. (1998) administered 1250 mg of oral vitamin D 2 once a week (equivalent to B171.5 mg/day) to a group of subjects with a mean age of 67 years and found that average 25OHD baseline level of 42.5 nmol/l rose to a mean value of 87.5 nmol/l after 8 weeks treatment; the authors did not report whether the subjects had normal or diminished bone mass nor the percentage of subjects who reached levels above 85 nmol/l.
Dawson Hughes et al. (1997) conducted studies in the US on a population with baseline 25OHD values of approximately 75 nmol/l. Administration of 17.5 mg/day of vitamin D 3 elevated 25OHD levels to 110 nmol/l after 3 months of treatment. It is most likely that the required dose differs according to the baseline level of 25OHD (oor 475 nmol/l). The present study is the first to be conducted in women over the age of 50 years with osteopenia/osteoporosis and with average 25OHD baseline values below 50 nmol/l. These 25OHD baseline values were similar to those previously reported for the Buenos Aires population in a study carried out in winter on subjects in the same age range (Oliveri et al., 2004) . Administration of a dose of 125 or 250 mg/day of vitamin D 2 during 3 months did not cause hypercalcemia. One patient in each group had hypercalciuria (4250 mg/ 24 h). After 3 months treatment, 75% of patients receiving 250 mg/day vitamin D 2 and 50% of those treated with 125 mg/ day of vitamin D 2 had reached 25OHD values above 85 nmol/l which is probably an adequate therapeutic level for patients with osteopenia/osteoporosis. Given the small number of patients in each group, results were also evaluated considering the groups receiving 125 or 250 mg/day of vitamin D 2 as a whole, and showed significant decreases in serum levels of mmPTH and BAP; both these effects are desirable therapeutic objectives of osteoporosis treatments. The lack of response of serum CTX may be attributed to the marked variation and dispersion of this bone resorption marker or to the small number of patients. The 25OHD values observed at 3 months in both groups treated with vitamin D 2 were higher than those observed at 2 months, so that the present study does not allow establishing the safety of long-term treatment with these doses. However, it is noteworthy that according to Vieth et al. (2001) , administration of 100 mg/day of vitamin D 3 did not cause 25OHD levels to change between months 3 and 5 of treatment. Both forms of vitamin D, ergocalciferol (D 2 ) or cholecalciferol (D 3 ), were generally considered equivalent. However, recent publications (Trang et al., 1998; Armas et al., 2004) suggest that vitamin D 2 is less effective than vitamin D 3 in raising serum 25OHD levels. Trang et al. (1998) administered both forms in a dose of 100 mg/day during 1 month. The increase in serum 25OHD levels was 1.7-fold higher with vitamin D 3 . Armas et al. (2004) showed that administration of a single dose of 1250 mg/day of vitamin D 2 or vitamin D 3 produced similar initial increases in 25OHD, but levels were maintained over a longer period with the vitamin D 3 compound, suggesting that potency of vitamin D 2 is less than one-third than that of vitamin D 3. The issue is still controversial with a dissenting observation reported recently (Rapuri et al., 2004) . Additional studies should be conducted to establish optimal dosing taking into account the form of vitamin D administered.
The limitations of the present study are: (1) all subjects presented spontaneously to our hospital for bone mass evaluation. It is possible, but unlikely, that this group of patients is not a representative sample of the entire postmenopausal population. As mentioned above, baseline 25OHD values were similar to those observed in previous studies (Oliveri et al., 2004) . (2) We did not study the effect of 20 mg/day of vitamin D 2 . However, previous studies, such as Heaney's report, have shown a limited increment in 25OHD levels with a daily dose of 25 mg of vitamin D 3 (Heaney et al., 2003a) . Further long-term studies À 12 to 24 monthsshould be performed to asses the safety and efficacy of using elevated doses of vitamin D in osteopenic/osteoporotic patients, and to establish the period throughout which these high doses should be maintained.
This study evidences the need to re-examine the doses used conventionally on these patients. In addition, our results show that with the administration of a dose of 125 or 250 mg/day of vitamin D 2 during 3 months most patients reached adequate levels of 25OHD, without causing any significant adverse effects.
